Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

About this update from Alnylam Pharmaceuticals, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1552,"height":440,"url":"https://media.zenfs.com/en/business-wire.com/99b10028afed5f34bf2874af82c571ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.4Nnkh3LW7d2nR_ecK.IUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3Mg--/https://media.zenfs.com/en/business-wire.com/99b10028afed5f34bf2874af82c571ff","width":960,"height":272},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/c9joR_VdzjZcqAqcv993sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02ODA-/https://media.zenfs.com/en/business-wire.com/99b10028afed5f34bf2874af82c571ff","width":1200,"height":340}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., May 04, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain.","length":440,"tagName":"p"},{"type":"text","content":"ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source.","length":579,"tagName":"p"},{"type":"text","content":"Additional analyses being presented at the congress include a pharmacodynamic analysis of TTR knockdown with vutrisiran across subgroups, a pooled safety analysis evaluating the incidence of TTR lowering with vitamin-A-related outcomes across clinical trial and real-world datasets, as well as the design of DemonsTTRate, a global, long-term observational study evaluating real-world use in patients with ATTR-CM.","length":413,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p...

More updates from Alnylam Pharmaceuticals, Inc.